DOWN-REGULATION OF PORCINE HEART DIAPHORASE REACTIVITY BY TRIMANGANESE HEXAKIS(3,5-DIISOPROPYL-SALICYLATE), Mn$_3$(3,5-DIPS)$_6$, AND DOWN-REGULATION OF NITRIC OXIDE SYNTHASE REACTIVITY BY Mn$_3$(3,5-DIPS)$_6$ AND Cu(II)$_2$(3,5-DIPS)$_4$

Billynda L. Booth, Eva Pitters, Bernd Mayer, and John R. J. Sorenson

Department of Medicinal Chemistry, College of Pharmacy, University of Arkansas for Medical Sciences Campus, Little Rock, AR 72205, USA; e-mail: sorensonjohnr@exchange.uams.edu

Institut für Pharmakologie und Toxikologie, Karl-Franzens-Universität Graz, A-8010 Graz, Austria

Abstract

Purposes of this work were to examine the plausible down-regulation of porcine heart diaphorase (PHD) enzyme reactivity and nitric oxide synthase (NOS) enzyme reactivity by trimanganese hexakis(3,5-diisopropylsalicylate), [Mn$_3$(3,5-DIPS)$_6$], as well as dicopper tetrakis(3,5-diisopropylsalicylate), [Cu(II)$_2$(3,5-DIPS)$_4$], as a mechanistic accounting for their pharmacological activities.

Porcine heart disease was found to oxidize 114 μM reduced nicotinamide-adenine-dinucleotide-3'-phosphate (NADPH) with a corresponding reduction of an equivalent concentration of 2,6-dichlorophenolindophenol (DCPIP). As reported for Cu(II)$_2$(3,5-DIPS)$_4$, addition of Mn$_3$(3,5-DIPS)$_6$ to this reaction mixture decreased the reduction of DCPIP without significantly affecting the oxidation of NADPH. The concentration of Mn$_3$(3,5-DIPS)$_6$ that produced a 50% decrease in DCPIP reduction (IC$_{50}$) was found to be 5 μM. Mechanistically, this inhibition of DCPIP reduction with ongoing NADPH oxidation by PHD was found to be due to the ability of Mn$_3$(3,5-DIPS)$_6$ to serve as a catalytic electron acceptor for reduced PHD as had been reported for Cu(II)$_2$(3,5-DIPS)$_4$. This catalytic decrease in reduction of DCPIP by Mn$_3$(3,5-DIPS)$_6$ was enhanced by the presence of a large concentration of DCPIP and decreased by the presence of a large concentration of NADPH, consistent with what had been observed for the activity of Cu(II)$_2$(3,5-DIPS)$_4$.

Oxidation of NADPH by PHD in the presence of Mn$_3$(3,5-DIPS)$_6$ and the absence of DCPIP was linearly related to the concentration of added Mn$_3$(3,5-DIPS)$_6$ through the concentration range of 2.4 μM to 38 μM with a 50% recovery of NADPH oxidation by PHD at a concentration of 6 μM Mn$_3$(3,5-DIPS)$_6$.

Conversion of [³H] l-Arginine to [³H] l-Citrulline by purified rat brain nitric oxide synthase (NOS) was decreased in a concentrated related fashion with the addition of Mn$_3$(3,5-DIPS)$_6$, as well as Cu(II)$_2$(3,5-DIPS)$_4$, which is an extention of results reported earlier for Cu(II)$_2$(3,5-DIPS)$_4$. The concentration of these two compounds required to produce a 50% decrease in l-Citrulline synthesis by NOS, which may be due to down-regulation of NOS, were 0.1 mM and 8 μM respectively, consistent with the relative potencies of these two complexes in preventing the reduction of Cytochrome c by NOS.

It is concluded that Mn$_3$(3,5-DIPS)$_6$, as has been reported for Cu(II)$_2$(3,5-DIPS)$_4$, serves as an electron acceptor in down-regulating PHD and both of these complexes down-regulate rat brain NOS reactivity. A decrease in NO synthesis in animal models of seizure and radiation injury may account for the anticonvulsant, radioprotectant, and radiorecovery activities of Mn$_3$(3,5-DIPS)$_6$ and Cu(II)$_2$(3,5-DIPS)$_4$.

Introduction

In neuronal cells of the brain [1] and many other cell types of other tissues [2] nitric oxide (N=O, NO) and l-Citrulline (l-Cit) are produced by constitutive cytosolic reduced nicotinamide-adenine-dinucleotide-3'-phosphate (NADPH)-dependent nitric oxide synthase (NOS) oxidation of l-Arginine (l-Arg) at a reductase-oxygenase coupled domain. Roles of NO have been reviewed by Moncada et al. [2], Moncada [3], Lancaster [4], Meller and Gebhart [5], and Nussler and Billiar [6]. It was pointed out by Moncada et al. [2] that as early as 1977 Miki et al. [7] suggested that the role
of NO in normal brain function was activation of cytosolic guanyl cyclase (GC). This activation by NO is now recognized as a feature of its role as a retrograde neurotransmitter [8] that has most recently been well characterized as a signal transduction mechanism within and between different areas of the brain [9]. Inducible NOS activity is also important in immune-mediated white blood cell responses to inflammation, cancer, and infection and cytokine mediation of many organ inflammatory diseases as well as pain [2,10].

Dicopper(II) tetrakis(3,5-diisopropylsalicylate), [Cu(II)₂(3,5-DIPS)₄], has been shown to have anti-inflammatory, antiulcer, anticonvulsant, anticancer, anticarcinogenic, antimutagenic, antiabetic, analgesic, radioprotectant, and radiorecovery activities and decreases ischemia-reperfusion injury [11 and references therein]. Following the report that Cu(II)₂(3,5-DIPS)₄ inhibits NADPH-dependent mixed function oxidase systems by serving as an electron acceptor, it was studied in the NADPH-dependent porcine heart diaphorase (PHD) system and in a NADPH-dependent tissue staining procedure used to detect NOS activity [10]. These studies revealed that Cu(II)₂(3,5-DIPS)₄ down-regulated PHD wherein PHD continued to oxidize NADPH, without reducing an obligate electron acceptor, dichlorophenolindophenol (DCPIP). It was also found that reducing equivalents derived from NADPH by PHD reduced Cu(I) to Cu(0) in a catalytic fashion causing a decrease in the reduction of DCPIP. These results lead to the provision of indirect evidence that the synthesis of NO by NOS in brain tissue sections was also decreased by incubating these tissue sections in medium containing Cu(II)₂(3,5-DIPS)₄ [10].

Epileptic seizures and radiation injury, both inflammatory disease states, may be associated with excessive production of NO[10]. Like Cu(II)₂(3,5-DIPS)₄, Mn₃(3,5-DIPS)₆ has also been found to be a rapidly acting anticonvulsant agent in preventing Metrazol- and Maximal Electroshock-induced seizures and to have sedative-hypnotic activities with ED₅₀ values ranging from 114 to 157 μmol/kg of body mass [12]. Like Cu(II)₂(3,5-DIPS)₄, Mn₃(3,5-DIPS)₆ also has radioprotectant and radiorecovery activities in that it also increases survival of whole body gamma-irradiated mice when non-toxic doses of Mn₃(3,5-DIPS)₆ are administered either before or after lethal irradiation [12]. Treatment with 80 μmol Mn₃(3,5-DIPS)₆/kg prior to low dose, LD₁₅, irradiation produced 100% survival, a 54% increase in survival, compared to vehicle-treated control mice (65% survival) [12]. Treatment with 40 μmol Mn₃(3,5-DIPS)₆/kg after high-dose, LD₁₂₂, irradiation produced a 229% increase in survival above vehicle-treated control mice (28% survival) [12]. The effective radioprotectant and radiorecovery doses are 1/9 to 1/10 the acutely toxic dose of Mn₃(3,5-DIPS)₆ and thus exhibit a large margin in safety for use as a radioprotectant and radiorecovery agent as found for Cu(II)₂(3,5-DIPS)₄ [13].

Either SOD-mimetic activity, facilitation of de novo synthesis of Cu₂Zn₂SOD or MnSOD, or synthesis of other Cu- and Mn-dependent tissue repair enzymes have been suggested as plausible modes of action for Cu(II)₂(3,5-DIPS)₄ and Mn₃(3,5-DIPS)₆ in accounting for their pharmacological activities [13]. It has since occurred to us that Mn₃(3,5-DIPS)₆ might also down-regulate NADPH-dependent enzymes such as PHD and NOS as has been reported for Cu(II)₂(3,5-DIPS)₄ [10].

To examine this question in a system which is less complicated than NOS but shown to be relevant to this enzyme system [10], the reactivity of Mn₃(3,5-DIPS)₆ was examined using PHD. These studies revealed that Mn₃(3,5-DIPS)₆ does down-regulate PHD. This complex as well as Cu(II)₂(3,5-DIPS)₄ were then examined for their ability to decrease the synthesis of l-Cit by authentic NOS using purified rat brain NOS.

We are reporting the down-regulation of PHD by Mn₃(3,5-DIPS)₆ wherein this complex does not inhibit PHD but serves as an electron acceptor in inhibiting reduction of DCPIP, the dye used as the obligate electron acceptor for PHD, and in serving as an electron acceptor this complex may down-regulate rat brain NOS in decreasing the synthesis of l-Cit.

Additional support for the suggestion that Cu(II)₂(3,5-DIPS)₄ may down-regulate NOS is also presented with the demonstration that this complex also decreases the synthesis of l-Citrulline and NO using purified rat brain NOS. It is plausible that the pharmacological activities of Mn₃(3,5-DIPS)₆ and Cu(II)₂(3,5-DIPS)₄ may be due in part to down-regulation of NOS.

Materials and Methods
Sodium 2,6-Dichlorophenolindophenol monohydrate [DCPIP], Trizma Base, Porcine Heart Diaphorase [9001-18-7] (PHD), and NADPH (all from the Sigma Chemical Co., Milwaukee, WI) and Horse Heart Cytochrome C Type III [9007-43-6] and Calmodulin [27-370-7]) (from Sigma, Deisenhofen, Germany) were used as purchased without further purification. Tritiated-l-Arginine
[(2,3,4,5-\textsuperscript{3}H)-L-Arg,\textsuperscript{3}H-L-Arg] and tritiated L-Citrulline [(2,3,4,5-\textsuperscript{3}H)-L-Citrulline, \textsuperscript{3}H-L-Cit] were obtained from Med Pro (Amersham), Vienna, Austria. Ultraviolet and visible absorbances were measured with a Hewlett Packard 8452A Diode Array Spectrophotometer. All glassware was thoroughly cleaned with either aqua regia or Citronox (Alconox Inc., New York, NY) and all plasticware was metal-free polypropylene. Deionized water, pH 7.5, was used throughout.

A 300 mM solution of Tris buffer and 10 mM solution of DCPIP were prepared in deionized water. A solution of 200 mM Mn\textsubscript{3}(3,5-DIPS)\textsubscript{6} was prepared by dissolving 15.4 mg of Mn\textsubscript{3}(3,5-DIPS)\textsubscript{6}(H\textsubscript{2}O)\textsubscript{1.25} (1531 Da) in 10 mL of ethanol. One mL of this solution was then diluted with 4 mL of ethanol. All concentrations of Mn\textsubscript{3}(3,5-DIPS)\textsubscript{6} are based upon a trinuclear form of this complex, Mn(II)\textsubscript{3}(3,5-DIPS)\textsubscript{6}(H\textsubscript{2}O) or Mn(III)\textsubscript{2}(II)(O)(3,5-DIPS)\textsubscript{6} [14-16], since these plausible structural forms of the complex were used to calculate the mass of complex required to prepare these solutions.

For studies employing a low concentration (38 \mu M) of NADPH (833.4 Da for the tetrosodium salt) and DCPIP (308.1 Da for the monohydrate) the enzyme reaction mixture contained 125 \mu L of 1.0 mM NADPH and 25 \mu L of 5 mM DCPIP in 3.125 \mu L of 300 mM Tris buffer. For studies employing a high concentration (114 \mu M) of NADPH and DCPIP the enzyme reaction mixture contained 375 \mu L of 1.0 mM NADPH and 75 \mu L of 5 mM DCPIP in 2.825 \mu L of 300 mM Tris buffer. Concentrations of these reactants in these reaction mixtures were arrived at through a series of experiments wherein equimolar concentrations of NADPH and DCPIP gave absorbances that were conveniently measured within the absorbance range of 0 to 2. These reactions were then started with the addition of 25 \mu L (1U) of PHD.

Visible and ultraviolet spectrophotometric measurements were performed at 600 nm for DCPIP and 340 nm for NADPH with zero absorbance set with buffer. When Mn\textsubscript{3}(3,5-DIPS)\textsubscript{6} was to be added to a reaction mixture, the studied concentration of Mn\textsubscript{3}(3,5-DIPS)\textsubscript{6}, or an equal volume of ethanol, was added to buffer to set zero absorbance and eliminate the absorbance due to the 3,5-DIPS ligand, \lambda\textsubscript{max} = 306 nm.

To determine the effect of Mn\textsubscript{3}(3,5-DIPS)\textsubscript{6} on the PHD enzyme system, a final concentration of 0.0 \mu M, 3.0 \mu M, 6.1 \mu M, or 12.2 \mu M [200 \mu L of ethanol or 50 \mu L, 100 \mu L, or 200 \mu L of the 200 \mu M Mn\textsubscript{3}(3,5-DIPS)\textsubscript{6} solution] was added to the reaction mixture. To examine Mn\textsubscript{3}(3,5-DIPS)\textsubscript{6} as an electron acceptor for NADPH reduced PHD, a concentration of 0.0 \mu M, 2.4 \mu M, 4.8 \mu M, 9.5 \mu M, 19 \mu M, or 38 \mu M Mn\textsubscript{3}(3,5-DIPS)\textsubscript{6} was added to the reaction mixture in the absence of DCPIP. The initial rate of 0.37 nmol/min for NADPH oxidation with the addition of 200 \mu L of ethanol, used to make the 0 \mu mol addition of Mn\textsubscript{3}(3,5-DIPS)\textsubscript{6} in the absence of DCPIP, was subtracted from initial rates obtained for additions of alcohol solutions of Mn\textsubscript{3}(3,5-DIPS)\textsubscript{6} used to demonstrate recovery of PHD activity. Initial rates were obtained by measuring changes in absorbance at 5 minutes following the addition of enzyme. All determinations were performed in triplicate and results presented as means ±S.E.M.

Decreases in absorbance at 340 nm for the oxidation of NADPH and 600 nm for the reduction of DCPIP were measured. It was found that the 340 nm absorbance of DCPIP decreased at the same rate as the rate of decrease of the 600 nm absorbance. For the complete NADPH and DCPIP reaction mixture the 340 nm absorbance is due to the combined absorbances of NADPH and DCPIP at 340 nm. The apparent rate of decrease of the 340 nm absorbance for the complete reaction mixture was found to be approximately twice, 0.224 nmol/min, the rate of decrease of the 600 nm absorbance, 0.099, due to the oxidation of NADPH and reduction of DCPIP.

Rat brain NOS was purified from recombinant baculovirus-infected cells as described elsewhere [17]. Synthesis of \textsuperscript{3}H-L-Cit and NO from \textsuperscript{3}H-L-Arg was determined by incubation of 0.2 to 0.3 \mu g of enzyme at 37°C for 10 min in 0.1 mL of a 50 mM triethanolamine hydrochloride buffer (pH 7.0) containing 0.1 mM \textsuperscript{3}H-L-Arg (~50,000 cpm), 0.2 mM NADPH, 5 \mu M flavin adenine dinucleotide, 10 \mu M tetrahydrobiopterin, 0.5 mM CaCl\textsubscript{2}, and 10 \mu g calmodulin /ml in the presence of Mn\textsubscript{3}(3,5-DIPS)\textsubscript{6} or Cu(II)\textsubscript{2}(3,5-DIPS)\textsubscript{4} (1048 Da for the dihydrate) added as a dimethylsulfoxide solution, followed by isolation of \textsuperscript{3}H-L-Cit by cation exchange chromatography which has been described in detail [18]. All determinations were performed in triplicate except the decrease in l-Cit caused by additions of 3 \mu M, 30 \mu M, or 0.5 mM Cu(II)\textsubscript{2}(3,5-DIPS)\textsubscript{4} and 1 mM Mn\textsubscript{3}(3,5-DIPS)\textsubscript{6}. These were all duplicate determinations except for the addition of 3 \mu M Cu(II)\textsubscript{2}(3,5-DIPS)\textsubscript{4} which was a single determination. Except for this single determination data are presented as means ±S.E.M.
Cytochrome c reductase activity was determined as described elsewhere [19]. Nitric oxide synthase (0.5 μg) was incubated in 0.2 ml of a 50 mM triethanolamine hydrochloride buffer, pH 7.0, containing 0.15 mM NADPH, 3 μM free Ca²⁺, 10 μM Cu(II)₃(3,5-DIPS)₄ or 100 μM Mn₃(3,5-DIPS)₆ and 0.2 mM cytochrome c at 37°C in the presence of 2 μg of calmodulin. Dimethylsulfoxide solutions of these complexes were used to make additions to the reaction mixture. The increase in absorbance at 500 nm was continuously monitored against blank samples containing buffer instead of enzyme, and the amount of enzymatically reduced cytochrome c was calculated using an extinction coefficient of 21 mM⁻¹ cm⁻¹. Data are results of a single experiment wherein the control was performed in triplicate and duplicate determinations were performed for the addition of both complexes. Results are presented as means ± S.E.M.

![Graph](attachment:image.png)

Figure 1. Maintenance of the initial rate of 114 μM NADPH oxidation (●) and the decrease in initial rate of 114 μM DCPIP reduction (○) in the presence of Mn₃(3,5-DIPS)₆.

Results

As shown in Figure 1, addition of 1 unit of PHD to a mixture of 114 μM NADPH and 114 μM DCPIP caused the reduction of the obligate electron acceptor DCPIP. The initial rate of decrease in absorbance at 340 nm appeared to be faster than the initial rate of decrease in absorbance at 600 nm due to an absorbance for DCPIP at 340 nm which also decreased at the same rate as the decrease in absorbance at 600 nm with the reduction of DCPIP. Addition of 3 to 12 μM Mn₃(3,5-DIPS)₆ produced a concentration related decrease in the initial rate of reduction of DCPIP with little change in the initial rate of oxidation of NADPH. The concentration of Mn₃(3,5-DIPS)₆ required to produce a 50% decrease in reduction of DCPIP by NADPH reduced PHD was 5.0 μM. These results demonstrated that PHD oxidation of NADPH occurred in the absence of the reduction of DCPIP, the obligate electron acceptor required for oxidation of NADPH by PHD.

Oxidation of NADPH by PHD in the absence of DCPIP reduction suggested that Mn₃(3,5-DIPS)₆ served as the obligate electron acceptor in enabling the continued oxidation of NADPH. This suggestion was examined by determining the oxidation of NADPH in the absence of DCPIP and the presence of increasing concentrations of 2.4 to 38 μM Mn₃(3,5-DIPS)₆ to a reaction mixture
containing 38 µM NADPH. Recovery of the initial rate of enzymatic oxidation of NADPH was directly related to increasing concentration of added Mn₃(3,5-DIPS)₆ as shown in Figure 2.

![Figure 2. Recovery of the maximum initial rate of oxidation of 38 µM NADPH in the presence of increasing concentration of Mn₃(3,5-DIPS)₆.](image)

The concentration of Mn₃(3,5-DIPS)₆ required to produce 50 percent recovery of the maximum initial rate of PHD activity in this system was 6 µM. Under these conditions the role of Mn₃(3,5-DIPS)₆ appears to be catalytic. This demonstration of enzyme activity recovery is consistent with the suggestion that Mn₃(3,5-DIPS)₆ does not inhibit PHD in causing the decrease in reduction of DCPIP in the complete NADPH-PHD-DCPIP reaction mixture. The decrease in reduction of DCPIP in the presence of Mn₃(3,5-DIPS)₆ which enables the oxidation of NADPH supports the suggestion that Mn₃(3,5-DIPS)₆ does not inhibit PHD but serves to "down-regulate" PHD reduction of DCPIP by serving as an electron acceptor for reduced PHD and enabling continued oxidation of NADPH. The decrease in reduction of DCPIP in the presence of Mn₃(3,5-DIPS)₆ can not be referred to as PHD inhibition and should be viewed as down-regulation of PHD in decreasing the reduction of DCPIP. This interpretation of these results suggested that this complex might also down-regulate NOS.

To examine the possibility that Mn₃(3,5-DIPS)₆ might down-regulate NOS, purified rat brain NOS was used to measure the conversion of l-Arg to l-Cit in the presence of Mn₃(3,5-DIPS)₆. As shown in Figure 3, incubation of NOS with concentrations of Mn₃(3,5-DIPS)₆ ranging from 10⁻⁸ M to 10⁻⁵ M caused a concentration related decrease in the conversion of l-Arg to l-Cit with an IC₅₀ for the decrease in l-Cit synthesis of 0.1 mM. Additions of 10⁻⁸ M to 10⁻⁵ M Cu(II)₂(3,5-DIPS)₄ to this enzyme system also produced a concentration related decrease in conversion of l-Arg to l-Cit with an IC₅₀ of 8 µM.

These results are consistent with the relative potencies of these two complexes in preventing the reduction of Cytochrome c by NOS as shown in Figure 4. A concentration of 10 µM Cu(II)₂(3,5-DIPS)₄ was more effective in decreasing Cytochrome c reduction than 67 µM Mn₃(3,5-DIPS)₆.
Discussion

Continuous oxidation of NADPH by PHD requires the presence of an electron acceptor. 2,6-dichlorophenolindophenol serves as an electron acceptor in its role as an in vitro substrate for the determination of PHD activity. The decrease in reduction of DCPIP in the presence of Mn$_3$(3,5-DIPS)$_6$ with continued oxidation of NADPH suggested that Mn$_3$(3,5-DIPS)$_6$ served as an electron acceptor in down-regulating, but not inhibiting, the reduction of DCPIP by NADPH-reduced PHD. Evidence for this down-regulation was obtained when the removal of DCPIP and addition of increasing concentration of Mn$_3$(3,5-DIPS)$_6$ caused a recovery of NADPH oxidation by PHD, demonstrating that PHD activity was not inhibited by Mn$_3$(3,5-DIPS)$_6$. 

Figure 3. Concentration dependent down-regulation of NOS by Mn$_3$(3,5-DIPS)$_6$ (●) and Cu(II)$_2$(3,5-DIPS)$_4$ (○).

Figure 4. Reduction of Cytochrome c by NOS (1) and the inhibition of Cytochrome c reduction due to the presence of 10 μM Cu(II)$_2$(3,5-DIPS)$_4$ (2) or 67 μM Mn$_3$(3,5-DIPS)$_6$ (3).
When recovery was determined for the enzyme system containing 114 μM NADPH and 1 unit of PHD, the addition of up to 48.8 μM Mn₃(3,5-DIPS)₆ did not yield 100% recovery of the initial rate of NADPH oxidation. However, the system containing 38 μM NADPH and 1 unit of PHD permitted maximum recovery of NADPH oxidation and 50 percent recovery was found for the addition of 6 μM Mn₃(3,5-DIPS)₆.

It is suggested that Mn₃(3,5-DIPS)₆ functions in a catalytic role as the electron acceptor in recovery of PHD activity. In the proposed mechanism in which Mn₃(3,5-DIPS)₆ serves as an electron acceptor in down-regulation of PHD, Mn(III) is reduced to Mn(II) which is in turn oxidized to Mn(III). As shown in Figure 5, oxidation of Mn(II), the product of PHD reduction, to Mn(III) by dissolved oxygen and the disproportionation of the resultant superoxide [12] and/or hydrogen peroxide [16,20] by Mn₃(3,5-DIPS)₆, must be relatively fast reactions compared to the slow rate of oxidation of NADPH and reduction of DCPIP by PHD. This rationale for the catalytic role of Mn₃(3,5-DIPS)₆ is the same as the proposed role of Cu(II)₂(3,5-DIPS)₄ in down-regulating NOS[10].

![Diagram](image-url)

**Figure 5.** Schemes for the oxidation of reduced PHD in the presence of DCPIP and with its replacement with Mn₃(3,5-DIPS)₆.

The net consumption of oxygen in these reactions could also offer an additional accounting for down-regulation of NOS which requires oxygen for the oxidation of L-Arg to L-Cit and NO. Disproportionation of superoxide by Mn₃(3,5-DIPS)₆ may also appear to reduce superoxide produced by NOS when NOS functions to generate superoxide via a one electron reduction of molecular oxygen [21].

Recovery studies also demonstrated that large concentrations of NADPH impede the recovery activity of Mn₃(3,5-DIPS)₆ which was not measurable in the system containing 114 μM NADPH with up to 48.8 μM Mn₃(3,5-DIPS)₆. Lowering the concentration of NADPH to 38 μM allowed the measurement of PHD recovery. The presence of 114 μM DCPIP may facilitate down-regulation of PHD by Mn₃(3,5-DIPS)₆ by forming a DCPIP-Mn-3,5-DIPS complex shown in Figure 6. The down-regulation concentration for 50 percent decrease in DCPIP reduction (DRC₅₀) in the 114 μM NADPH and DCPIP system was 5 μM Mn₃(3,5-DIPS)₆. However, the presence of 114 μM NADPH may inhibit or decrease the effectiveness of Mn₃(3,5-DIPS)₆ in facilitation recovery of NADPH as a result of the formation of an NADPH complex (Figure 6).
Figure 6. Proposed structure of the $\text{Mn}_3(3,5\text{-DIPS})_6\text{-NADPH}$ complex (top) that impedes PHD recovery activity when a large concentration of NADPH is present and the DCPIP-$\text{Mn}_3(3,5\text{-DIPS})_6$ complex (bottom) that facilitates down-regulation of PHD when a large concentration of DCPIP is present.

Non-toxic doses of manganese complexes, which would supply less than the daily required intake of manganese, have been shown to have beneficial anticonvulsant effects in models of seizure and radiation injury [11,12]. Very small doses of $\text{Mn}_3(3,5\text{-DIPS})_6$ have both radioprotectant and radiorecovery activities [12]. The plausible down-regulation of NOS by $\text{Mn}_3(3,5\text{-DIPS})_6$ may account for its anticonvulsant activity in the Metrazole and Electroshock models of seizure [12]. In addition to Metrazole-induced [22] and electrically kindled seizures [23], seizures induced by N-methyl-D-aspartate (NMDA) receptor activation [24-26], tacrine [27], and sodium nitroprusside [$\text{Na}_3\text{Fe(III)(CN)}_6(\text{NO})$] [26] are mediated via the NO-GC-NMDA pathway. However, pilocarpine-induced seizures were paradoxically facilitated by blockade of the NMDA receptor and inhibition of NOS [28]. Except for these as yet unexplained paradoxical results, all other results support hypotheses that NO synthesized by NOS from l-Arg and subsequent NO activation of GC leading to NMDA-receptor activation contribute to seizure states and that anticonvulsant activities of both $\text{Mn}_3(3,5\text{-DIPS})_6$ are consistent with its possible down-regulation of NO synthesis.

Impedence of some step in the NOS-NO-cGMP-glutamate-NMDA-receptor pathway accounts for the anesthetic activity of ketamine, kainate, quisqualate, l-Glu, l-Asp [29], halothane [30-32], l-NAME [30], nitrous oxide, and isoflurane [32]. Decreased consciousness and sedation are also caused by interruption of this pathway [30] and may account for the anticonvulsant activity of $\text{Mn}_3(3,5\text{-DIPS})_6$ and Cu(II)$_2(3,5\text{-DIPS})_4$ [11].

Radiation injury is either a local or systemic inflammatory disease depending upon either focal-tissue or whole-body radiation exposure. Since NO has roles in perception of inflammatory insults and mediation of the host response to inflammation [10 and citations therein] and the modulation of NO synthesis is required to bring about cessation of this component of the
inflammatory response, the down-regulation of NOS by Mn$_3$(3,5-DIPS)$_6$ and Cu(II)$_2$(3,5-DIPS)$_4$ may account for the increase in survival of lethally irradiated mice treated with these complexes [12,13].

It is generally accepted that NOS has features similar to Cytochrome p-450 in incorporating one atom of activated dioxygen into substrate and requiring activation of two molecules of dioxygen in the syntheses of L-Cit and NO from L-Arg [32-35]. However, this mechanism has been questioned by Leone et al. [36] who provided evidence consistent with NOS being a dioxygenase wherein both atoms of dioxygen are incorporated into L-Arg to give the two NOS products, NO and L-Cit. While both enzymatic transformations are plausible, the efficiency of a dioxygenase makes this possibility attractive. The isolation of NO-$\cdot$-arginine from a NOS reaction mixture may be a P-450-like oxidation product but a kinetically less likely product. In this event, Mn$_3$(3,5-DIPS)$_6$ being an effective SOD-mimetic or serving as an electron acceptor might also down-regulate this P-450 activity as has been shown for Cu(II)$_2$(3,5-DIPS)$_4$ and other Cu complexes [37-39].

Nitric oxide is a reactive molecule with a half-life of seconds in biological systems [40] and would most likely react with many cellular and extracellular components, causing marked chemical injury before it diffuses to a target cell. Since NO is reactive, NOS may include a component which accepts newly synthesized NO and serves as its transporter. Consequently, suggestions that NO is transported via either an organic thionitrite, nitrosoamine, alkyl and aryl nitrite, or peroxy nitrite or Fe, Mn, or Cu nitrosyl complexes [40,41] merit consideration and further study. While all of these potential transport forms of NO are plausible, evidence does exist for thionitrites of cysteine and penicillamine [41] in serving as organic NO transporting compounds and a NO complex of Fe, Na$_2$Fe(III)(CN)$_5$(NO), is a well known NO transporting complex used to rescue patients in hypertensive crises. It is also plausible that nanomolar or lower concentrations of a Mn(II) or Cu(II) complex, smaller than the concentration that might down-regulate NOS, can serve as NO transporting complexes, O=N-Mn(III)L$_3$ or O=N-Cu(III)L$_3$. This point may be particularly relevant to the observation that the IC$_{50}$ for Mn$_3$(3,5-DIPS)$_6$ in decreasing NOS activity was 0.1 mM supporting the notion that a lower and more physiologically relevant concentration would be more likely to form a NO complex without decreasing NO synthesis. The reported [42] potentiation of the NO-mediated increase in cGMP by a small molecular mass Mn(II) complex (SC52608), while suggested to be due to its SOD-mimetic activity [42], could also be due to its ability to form a O=N-Mn(III) complex and serve as a NO transporting agent. There are many Mn-and Cu-dependent enzymes and their facilitated activation by treatment with a Mn and or Cu complex also offers a plausible accounting for the pharmacological effects of low molecular mass Mn and Cu complexes [13]. Manganese- and Cu-dependent enzymes may also have a biochemical role in mediating normal physiologic roles of NO. Manganese and Cu requirements for normal physiological and biochemical function of NO-mediated events merit further investigation.

Acknowledgments

We are indebted to Harry P. Ward, Chancellor of the University of Arkansas for Medical Sciences Campus, the Winthrop Rockefeller Foundation, the Arkansas Medical, Dental, and Pharmaceutical Association, the National Institute of Health Research Apprenticeship Program, grant number 5R25RR10281-03 and a grant P11478 from the Fonds zur Foerdurung der Wissenschaftlichen Forschung in Austria for financial support.

References

[1] H. H. W. Schmidt, P. Wilke, B. Evers, E. Bohme, Biochem. Biophys. Res. Comm., 165 (1989) 284.
[2] S. Moncada, R. M. J. Palmer, E. A. Higgs, Pharmacol. Rev., 43 (1991) 109.
[3] S. Moncada, R. M. J. Palmer, Trends Pharmacol. Sci., 12 (1990) 130.
[4] J. R. Lancaster, Jr., Amer. Scient., 80 (1992) 248.
[5] S. T. Meller, G. F. Gebhart, Pain, 52 (1993) 127.
[6] A. K. Nussler, T. R. Billar, J. Leuk. Biol., 54 (1993) 171.
[7] N. Miki, Y. Kawabe, K. Kuriyama, Biochem. Biophys. Res. Comm., 75 (1977) 851.
[8] R. G. Knowles, M. Palacios, R. M. J. Palmer, S. Moncada, Proc. Natl. Acad. Sci. USA, 86 (1989) 5159.
[9] E. Southam, J. Garthwaite, Neuropharmacol., 32 (1993) 1267.
[10] J. G. L. Baquial, J. R. J. Sorenson, J. Inorg. Biochem., 60 (1995) 133.
[11] J. R. J. Sorenson, Prog. Med. Chem., 26 (1989) 437.
Vol. 6, No. 2, 1999  

Down-Regulation of Porcine Heart Diaphorase Reactivity by Trimanganese Hexaakis-(3,5-Disopropylsalicylate),

[12] J. R. J. Sorenson, L. S. F. Soderberg, L. W. Chang, W. M. Willingham, M. L. Baker, J. B. Barnett, H. Salari, K. Bond, *Eur. J. Med. Chem.*, **28** (1993) 221.

[13] J. R. J. Sorenson, L. S. F. Soderberg, L. W. Chang, *Proc. Soc. Exptl. Biol. Med.*, **210** (1995) 191.

[14] B. O. West, *Polyhedron*, **8** (1978) 219.

[15] J. B. Vincent, H. R. Chang, K. Folting, J. C. Huffman, G. Christou, D. N. Hendricsson, *J. Am. Chem. Soc.*, **109** (1987) 5703.

[16] J. B. Vincent, H.-L. Tsai, A. G. Blackman, S. Wang, P. D. W. Boyd, K. Folting, J. C. Huffman, E. B. Lobkovsky, D. N. Hendrikson, G. Christu, *J. Am. Chem. Soc.*, **115** (1993) 12353.

[17] H. Harteneck, P. Klatt, K. Schmidt, B. Mayer, *Biochem. J.*, **304** (1994) 683.

[18] B. Mayer, P. Klatt, E. R. Werner, K. Schmidt, *Neuropharmacol.*, **33** (1994) 1253.

[19] P. Klatt, B. Heinzel, M. John, M. Kastner, T. Bohme, B. Mayer, *J. Biol. Chem.*, **267** (1992) 11374.

[20] P. A. Gonzalez, T. Zhuang, S. R. Doughtrow, B. Malfroy, P. F. Benson, M. J. Menconi, M. P. Fink, *J. Pharmacol. Exptl. Therap.*, **275** (1995) 798.

[21] S. Pou, W. S. Pou, D. S. Bredt, S. H. Snyder, G. M. Rosen, *J. Biol. Chem.*, **267** (1992) 24173.

[22] J. A. Ferrendelli, A. C. Blank, R. A. Gross, *Brain Res.*, **200** (1980) 93.

[23] M. E. Gilbert, *Brain Res.*, **463** (1988) 90.

[24] S. H. Synder, D. S. Bredt, *Trends Pharmacol. Sci.*, **12** (1991) 125.

[25] E. H. F. Wong, J. A. Kemp, T. Priestly, A. R. Knight, G. N. Woodruff, L. L. Iversen, *Proc. Natl. Acad. Sci. USA*, **83** (1986) 7104.

[26] G. De Sarro, E. D. Di Paola, A. De Sarro, M. J. Vidal, *Eur. J. Pharmacol.*, **230** (1993) 151.

[27] G. Bagetta, M. Iamnone, A. M. Scorsa, G. Nistico, *Eur. J. Pharmacol.*, **213** (1992) 301.

[28] M. S. Starr, B. S. Starr, *Pharmacol. Biochem. Behav.*, **45** (1993) 321.

[29] T. Yamamura, K. Harada, A. Okamura, O. Kemmotsu, *Anesth.*, **72** (1990) 704.

[30] R. A. Johns, J. C. Mosciki, C. A. DiFazio, *Anesth.*, **77** (1992) 779.

[31] Y.-X. Wany, A. Abdelrahman, C. C. Y. Pang, *J. Cardiovas. Pharmacol.*, **22** (1993) 571.

[32] T. W. McPherson, J. R. Kirsh, L. E. Moore, R. J. Traystman, *Anesth. Anal.*, **77** (1993) 891.

[33] D. J. Stuehr, N. S. Kwon, C. F. Nathan, O. W. Griffin, P. L. Feldman, J. Wiseman, *J. Biol. Chem.*, **266** (1991) 6259.

[34] T. Yamamura, K. Harada, A. Okamura, O. Kemmotsu, *Anesth.*, **72** (1990) 704.

[35] R. A. Johns, J. C. Mosciki, C. A. DiFazio, *Anesth.*, **77** (1992) 779.

[36] Y.-X. Wany, A. Abdelrahman, C. C. Y. Pang, *J. Cardiovas. Pharmacol.*, **22** (1993) 571.

[37] T. W. McPherson, J. R. Kirsh, L. E. Moore, R. J. Traystman, *Anesth. Anal.*, **77** (1993) 891.

[38] D. J. Stuehr, N. S. Kwon, C. F. Nathan, O. W. Griffin, P. L. Feldman, J. Wiseman, *J. Biol. Chem.*, **266** (1991) 6259.

[39] K. A. White, M. A. Marletta, *Biochem.*, **31** (1992) 6627.

[40] P. Klatt, K. Schmidt, G. Uray, B. Mayer, *J. Biol. Chem.*, **268** (1993) 14781.

[41] A. M. Leone, R. M. J. Palmer, R. G. Knowles, P. L. Francis, D. S. Ashton, S. Moncada, *J. Biol. Chem.*, **226** (1991) 23790.

[42] C. Richter, A. Azzi, U. Weser, A. Wendeh, *J. Biol. Chem.*, **252** (1977) 5061.

[43] U. Weser, C. Richter, A. Wendeh, M. Younes, *Bioinorg. Chem.*, **8** (1978) 201.

[44] J. Werringloer, S. Kawano, N. Chacos, R. W. Eastbrook, *J. Biol. Chem.*, **254** (1979) 11839.

Received: January 27, 1999 - Accepted: February 11, 1999 -
Received in revised camera-ready format: March 19, 1999

120